1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Merck & Co. and Daiichi’s Phase II ADC Hit Raises Expectations

 
• By Elizabeth Cairns

Ifinatamab deruxtecan, a potential first-in-class B7-H3-targeted conjugate, looks promising – but the real test is to come.    

Lungs

The Phase III trial of Merck & Co., Inc. and Daiichi Sankyo Co., Ltd.’s ifinatamab deruxtecan (I-DXd) in small-cell lung cancer (SCLC) will report in 2027, and following the recent misfire with another of the partners’ antibody-drug conjugates, patritumab deruxtecan, they need this one to hit.

Key Takeaways
  • Mid-stage data suggest Merck & Co and Daiichi Sankyo’s antibody-drug conjugate ifinatamab deruxtecan could be competitive in small-cell lung cancer.
  • On a cross-trial basis, it looks better...

Fortunately, Merck and Daiichi will be more sanguine about the 2027 readout following encouraging data from a Phase II trial of I-DXd. Disclosed on 7 September at the World Conference...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

More from R&D

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.